Bristol Myers Squibb's Opdivo reign expands with new earlier-stage melanoma nod

Bristol Myers Squibb’s star Opdivo now can lay claim to an earlier melanoma stage with a new approval that “reinforces the company’s legacy” in treating the cancer type, it said.

The FDA blessed the PD-1 inhibitor as a post-surgical adjuvant therapy in completely resected stage 2B or 2C melanoma in patients 12 years of age or older, marking Opdivo’s fifth nod in earlier cancer stages, the company said in a release.